Research and original publication material
Novartis AG Receives Patent in India for Glycoside Derivatives to Treat Diabetes — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
NOVARTIS AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. The disease focus areas of Novartis include Cancer, Cardio-Metabolic, Immunology and Dermatology, Neuroscience, Ophthalmology, and Respiratory. The main platform used by Novartis includes cell and gene therapy.
In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.
Novartis AG has filed a patent application in India with application number as 4342/DELNP/2012 that is titled GLYCOSIDE DERIVATIVES AND USES THEREOF. This patent application has been granted as Patent Number 314402.
The invention covers chemical compounds, wherein the patent claims relate to compounds represented by formula (I), wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims 54-86 disclose the crystalline form of already known compounds hence these claims fall within the scope of Section 3(d) of the Indian Patent Act.
As a response to said objection, the applicant responded by submitting technical and scientific arguments to show that new chemical entity is formed by using chemical reactions, which were sufficient to prove the novelty and inventive step of this invention, thereby resulting in grant of this patent.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to Novartis AG Receives Patent in India for
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Discuss a research questionSource and context: Original GIPResearch.com publication dated 2019-08-03. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting